#78
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to understand that higher-potency cannabis products significantly impair driving ability, which is directly relevant when counseling patients about safe use and assessing impairment risk. This evidence supports clinical guidelines for screening patients about cannabis use before prescribing medications that also affect cognition or motor function, and helps inform discussions about occupational safety with patients who drive professionally. The data strengthens clinicians’ ability to provide evidence-based guidance on product selection and consumption patterns that minimize harm to patients and the public.
This study examined how cannabis potency affects driving performance in a simulated environment, finding that higher THC concentrations significantly impaired critical driving tasks including reaction time, lane positioning, and hazard perception. The research demonstrates a dose-dependent relationship between cannabis potency and driving impairment, with effects persisting beyond the period of subjective intoxication, which has important implications for clinicians counseling patients about cannabis use and driving safety. These findings support current public health messaging that advises against driving after cannabis use and suggest that patient education should specifically address the potency of products being consumed, as modern high-potency formulations carry greater impairment risk than historical cannabis preparations. Clinicians should incorporate driving risk assessment into cannabis use discussions, particularly for patients in occupations requiring vehicle operation or those with safety-sensitive responsibilities. The practical takeaway is that clinicians should ask patients about their driving habits when recommending or discussing cannabis use, inform them that higher-potency products increase impairment severity, and counsel them to avoid driving for several hours after use regardless of subjective feeling of intoxication.
“What this research confirms clinically is what I tell patients every day: the relationship between THC potency and driving impairment is real and dose-dependent, which means we need to move beyond ‘just don’t drive high’ to actually helping people understand their individual impairment threshold—something that varies based on tolerance, metabolism, and the specific cannabinoid profile they’re using.”
? As cannabis legalization expands across jurisdictions, clinicians should be aware that recent research demonstrates dose-dependent impairment of simulated driving performance with smoked cannabis, particularly at higher potency levels—a finding with direct relevance to patient counseling about cannabis use and safety. While laboratory driving simulations have known limitations in predicting real-world outcomes, and individual variability in cannabinoid metabolism and tolerance complicates risk assessment, the evidence supports a clear conversation with patients about impairment risks, especially those who drive or operate machinery. The increasing potency of commercially available cannabis products means that patients may unknowingly consume amounts that impair driving ability, even if they do not feel subjectively intoxicated. Clinicians should routinely ask about cannabis use patterns and driving habits, provide explicit guidance that cannabis use impairs driving similarly to alcohol, and consider documenting these counseling interactions in the medical record given the medicolegal implications
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
Read next
